Itoh K, Hara T, Shibata N
Division of Molecular Cardiology, Center for Adult Diseases, Osaka, Japan.
Biochim Biophys Acta. 1992 Feb 3;1133(3):286-92. doi: 10.1016/0167-4889(92)90049-h.
Recently, one of the authors (K.I.) and other investigators reported that myosin light chain (MLC) of smooth muscle (gizzard, arterial and tracheal) was diphosphorylated by myosin light chain kinase (MLCK) and that diphosphorylated myosin showed a marked increase in the actin-activated myosin ATPase activity in vitro and ex vivo. In this study, we prepared myosin, actin, tropomyosin (human platelet), MLCK (chicken gizzard) and calmodulin (bovine brain) and demonstrated diphosphorylation of MLC of platelet by MLCK in vitro. Our results are as follows. (1) Platelet MLC was diphosphorylated by a relatively high concentration (greater than 20 micrograms/ml) of MLCK in vitro. As a result of diphosphorylation, the actin-activated myosin ATPase activity was increased 3 to 4-fold as compared to the monophosphorylation. (2) Both di- and monophosphorylation reactions showed similar Ca2+, KCl, MgCl2-dependence. Maximal reaction was seen at [Ca2+] greater than 10(-6) M, 60 mM KCl and 2 mM MgCl2. This condition was physiological in activated platelets. (3) Di- and monophosphorylated myosin showed similar Ca2+, KCl-dependence of ATPase activity but distinct MgCl2-dependence. Diphosphorylated myosin showed maximal ATPase activity at 2 mM MgCl2 and monophosphorylated myosin showed a maximum at 10 mM MgCl2. (4) The addition of tropomyosin stimulated actin-activated ATPase activity in both di- and monophosphorylated myosin to the same degree. (5) ML-9, a relatively specific inhibitor of MLCK, inhibited the aggregation of human platelets induced by thrombin ex vivo in a dose-dependent manner. Moreover, this drug also partially inhibited both di- and monophosphorylation reactions and actin-activated ATPase activity. On the other hand, H-7, a synthetic inhibitor of protein kinase C, had little effect on the aggregation of human platelets induced by thrombin ex vivo. From these results, we conclude that diphosphorylation of platelet myosin by MLCK may play an important role in activated platelets in vivo.
最近,本文作者之一(K.I.)及其他研究人员报道,平滑肌(砂囊、动脉和气管)的肌球蛋白轻链(MLC)可被肌球蛋白轻链激酶(MLCK)双磷酸化,且双磷酸化的肌球蛋白在体外和体内的肌动蛋白激活的肌球蛋白ATP酶活性均显著增加。在本研究中,我们制备了肌球蛋白、肌动蛋白、原肌球蛋白(人血小板)、MLCK(鸡砂囊)和钙调蛋白(牛脑),并在体外证实了MLCK可使血小板的MLC发生双磷酸化。我们的结果如下:(1)在体外,血小板MLC可被相对较高浓度(大于20微克/毫升)的MLCK双磷酸化。双磷酸化的结果是,与单磷酸化相比,肌动蛋白激活的肌球蛋白ATP酶活性增加了3至4倍。(2)双磷酸化和单磷酸化反应均表现出相似的Ca2+、KCl、MgCl2依赖性。在[Ca2+]大于10^(-6) M、60 mM KCl和2 mM MgCl2时观察到最大反应。这种条件在活化血小板中是生理性的。(3)双磷酸化和单磷酸化的肌球蛋白在ATP酶活性的Ca2+、KCl依赖性方面相似,但在MgCl2依赖性方面不同。双磷酸化的肌球蛋白在2 mM MgCl2时表现出最大ATP酶活性,单磷酸化的肌球蛋白在10 mM MgCl2时表现出最大值。(4)添加原肌球蛋白对双磷酸化和单磷酸化肌球蛋白中肌动蛋白激活的ATP酶活性的刺激程度相同。(5)ML-9是一种相对特异性的MLCK抑制剂,在体内可剂量依赖性地抑制凝血酶诱导的人血小板聚集。此外,该药物还部分抑制双磷酸化和单磷酸化反应以及肌动蛋白激活的ATP酶活性。另一方面,蛋白激酶C的合成抑制剂H-7对凝血酶在体内诱导的人血小板聚集几乎没有影响。从这些结果中,我们得出结论,MLCK使血小板肌球蛋白双磷酸化可能在体内活化血小板中起重要作用。